Interview with Jose Almeida Bastos, Director President, MSD Brasil
When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which…
Address: R. Cônego Felipe, 365 – Taquara – Rio de Janeiro – RJ
Tel: (21) 2159-2600
Web: http://www.bago.com.br/web/cgi/cgilua.exe/sys/start.htm?tpl=home
With an innovative profile, Bagó Group is a leader in healthcare in Latin America. It is formed by a pool of solid enterprises, oriented around healthcare and improving quality of life.
Proud to be Latin American, the group was founded in 1934 in Argentina, and today is one of the most significant in the world pharmaceutical market. With an outstanding presence in Latin America and extending its roots over the world, it counts on over 6500 employees that share the same values of innovation and the same ideals of growth.
Laboratórios Bagó was established in Brazil in 2002, with the aim of working in the pharmaceutical industry as a tool for building a strong laboratory, and now counts a multidisciplinary team composed by over 180 professionals.
It is an intellectual leader, a reference in the Marketing business and has worked with Merck, Glaxo and Roche Laboratories.
Hydrophilic Array, Trifamox IBL, Magnesium Valproate, Alprazolam Sublingual, Talniflumate
When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which…
In an exclusive interview, Otto Philipp Braun, part of medtech giant B. Braun’s family dynasty, discusses his achievements as MD in Brazil, the company’s operations in the country and globally, as…
When we met you in 2007, as the head of the former Igefarma, the company was undergoing a transition – from branded generics into dermocosmetics and women’s health. But since…
Rogerio, you were one of the people responsible for integrating two well-established companies in the Brazilian market with the acquisition of Exel by DHL in late 2005. How challenging was…
You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your background and experience at…
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
With its huge market of 186 million people; its current position as the largest pharma market in Latin America, with strong growth projected; the influx of foreign and local…
See our Cookie Privacy Policy Here